Using proteomics and other advanced tools of molecular biology, an international team of researchers led by a group from Karolinska Institutet have found a novel way to diagnose Alzheimer’s disease by blood analysis, with a potential to uncover the underlying cause of the disease and prevent its development.
When we age, so do proteins in our body, including long-lived proteins in our blood, such as albumin. One of the major manifestations of protein aging is the loss of ammonia, known as deamidation. As deamidation products accumulate, the protein molecule loses its structure, function and solubility, and starts aggregating.
The link between deamidation and neurodegeneration has long been postulated, but only now has decisive evidence been obtained. As discovered by an international group of researchers led by Roman Zubarev, MBB, development of Alzheimer’s disease (AD) is not only associated with build-up of deamidated albumin, but also with diminished defenses against deamidation in form of natural deamidation-specific antibodies. As deamidation of blood proteins appears to precede all other damaging processes in AD, fighting its build-up may prevent neurodegeneration and prolong healthy life. The study is published in Alzheimer’s & Dementia.
Bone proteomics could reveal how long a corpse has been underwater
Jijing Wang et al, Testing the link between isoaspartate and Alzheimer’s disease etiology, Alzheimer’s & Dementia (2022). DOI: 10.1002/alz.12735
Novel way to diagnose Alzheimer’s disease by blood analysis (2022, August 8)
retrieved 8 August 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.